Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Amerikaanse aandelen   /   Cannabis aandelen

Amerikaanse aandelen« Terug naar discussie overzicht

Cannabis aandelen

Volgen
8.267 Posts
Pagina: «« 1 ... 128 129 130 131 132 ... 414 »» | Laatste | Omlaag ↓
  1. Empros 8 juni 2018 23:51
    quote:

    loserandpoor schreef op 8 juni 2018 11:15:

    ik heb Cannabis Wheaton Income in mijn bezit, nog iemand ?
    (gekocht aan 1.58 cad zijn teruggevallen naar 1.30 cad )
    bijkopen, verkopen ?? graag jullie mening
    CBW = XLY

    seekingalpha.com/instablog/48794816-j...

    www.stockwatch.com/News/Item.aspx?bid...

    Bijgekocht. Komt goed op de lange rit!
  2. [verwijderd] 9 juni 2018 12:29
    quote:

    eri09 schreef op 8 juni 2018 16:25:

    [...]

    zij het gisteren ook al dit was verwacht en wel in geprijsd, denk dat we volgende week wel rustig kunnen stijgen, en misschien vandaag aan het einde van de dag dat er weer vele instappen
    klopte vandaag aardig dus nu maar hopen dat het volgende week gewoon dik up gaat, can en aph gewoon groen en acb ook mooi teruggekomen van een dikke -7 naar -3% dus ben niet ontevreden met vandaag als ik heb begin van de dag bekijk want dat was toch wel weer als van ouds bloed door de straten.

    op naar maandag
  3. [verwijderd] 9 juni 2018 12:36
    quote:

    eri09 schreef op 9 juni 2018 12:29:

    [...]

    klopte vandaag aardig dus nu maar hopen dat het volgende week gewoon dik up gaat, can en aph gewoon groen en acb ook mooi teruggekomen van een dikke -7 naar -3% dus ben niet ontevreden met vandaag als ik heb begin van de dag bekijk want dat was toch wel weer als van ouds bloed door de straten.

    ff nog wat nieuws wat wel eens voor spektakel kan gaan zorgen maandag

    www.bnnbloomberg.ca/trump-signals-sup...

    ook interesant www.bnnbloomberg.ca/commodities/video...

    op naar maandag
  6. [verwijderd] 11 juni 2018 16:32
    quote:

    Onbekende schreef op 11 juni 2018 16:23:

    Iemand nog nieuws opgemerkt van WeedMD? Bijna alles weer in het rood, terwijl dit aandeel op +6% staat.
    WeedMD Secures Cannabis Cultivation Licence for its Large-scale Modern Greenhouse

    Toronto, Canada, June 11, 2018 – WeedMD Inc. (TSX-V:WMD) (OTC:WDDMF) (FSE:4WE) (“WeedMD” or the “Company”), a federally-licensed producer and distributor of medical cannabis, is pleased to announce that it has secured its Health Canada Cultivation Licence for the first four grow rooms within its 220,000 sq. ft. Phase I retrofit of its 610,000 sq. ft. modern greenhouse in Strathroy, Ontario.

    With a fully-funded 220,000 sq. ft. retrofit in its final stage, the Company will progressively bring a total of 20 grow rooms online over the coming months. The first set of cannabis plants are ready to be transferred to the new facility over the next couple of weeks from the Company’s fully-licensed and operational facility in Aylmer, Ontario, located 60 km away. When Phase I is complete, WeedMD’s production profile has the possibility of increasing from 1,500 kg to more than 21,000 kg per annum. Additionally, the Company’s fully-funded Phase II expansion is currently underway with an incremental 175,000 sq. ft conversion representing the possibility of an additional yield of 12,000 kg bringing the yearly total to the possibility of more than 33,000 kg by year-end 2018. Once fully retrofitted - bringing total square footage to 610,000 sq. ft. - the entire facility would have the possibility of producing over 50,000 kg annually.

  13. zonnedaal 12 juni 2018 07:11
    quote:

    kweetje schreef op 11 juni 2018 22:32:

    Is er een reden waarom aurora bijna een procent en organigram meer dan een procent stijgen in de laatste minuut? Wordt de koers naar beneden geduwd om dan groot in te kopen?
    Nu wiet gelegaliseerd is gewoon Aurora op de plank leggen. Aurora is wereldwijde marktleider, veruit de grootste en goed gefinancierd.
  14. zonnedaal 12 juni 2018 07:18
    quote:

    geen naam schreef op 12 juni 2018 00:06:

    [...]
    Dit was slechts een stemming er volgen nog meer ,de echte legalisatie duurt nog ff en dus ook het vuurwerk.

    Er zijn wat (kleine tot middelgrote) aanpassingen aan het wetsvoorstel gedaan. Dat moet eerst weer terug naar de House of Commons (in liberale handen), daarna gaan de goedgekeurde aanpassingen weer terug naar het Senaat om daar ook weer over te stemmen. Verwachting is dat in september de praktische invoering kan starten.
  16. Weetwel 12 juni 2018 14:26
    Ascent to supply up to 20,000 kg of dried cannabis flower and up to 6,000 kg of cannabis trim per year
    TSX: ACB
    EDMONTON, June 11, 2018 /CNW/ - Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) today announced that it has signed a cannabis flower and trim supply agreement (the "Agreement") with Ascent Industries Corp's ("Ascent") wholly-owned subsidiary, Agrima Botanicals Corp. ("Agrima"), a licensed producer of medical cannabis pursuant to Health Canada's Access to Cannabis for Medical Purposes Regulations ("ACMPR").
    Under the terms of the Agreement, Agrima will supply Aurora with up to 20,000 kg of dried cannabis flower and up to 6,000 kg of cannabis trim per year from its Canadian cultivation facilities. The Agreement is effective for a term of five years, subject to a 12,000 kg per year minimum.
    "The agreement with Ascent brings further differentiation to Aurora's growing portfolio of products," said Terry Booth, CEO. "Expanding product choice to our various audiences through quality operators such as Agrima positions us well to accelerate growth. Furthermore, the relationship provides an opportunity to potentially source additional, higher-margin derivative products down the line."
    Philip Campbell, CEO and Director of Ascent added, "We are delighted to be selected as a supplier to Aurora, a leader in the global cannabis sector. Agrima is committed to providing high-quality cannabis to both consumers and strategic partners, which this new agreement is testament to. We believe this represents the beginning of a strong strategic relationship with Aurora, one which will benefit both companies for years to come."
    Ascent's wholly-owned subsidiary, Agrima will supply Aurora with dried cannabis flower and trim grown at its facilities in Pitt Meadows, British Columbia. Once operational, the 600,000 square foot, automated cultivation facility will have a total cultivation capacity of approximately 60,000 kg of cut flower per year. Agrima anticipates receiving Health Canada approval towards the end of calendar 2018, and anticipates shipping its first products in Q1 2019.

    Bron: investor.auroramj.com/#
  17. Weetwel 12 juni 2018 14:26
    AURORA CANNABIS TO ACQUIRE CANNABIS SCIENCE LEADER ANANDIA LABORATORIES INC.×
    Boosting IP Portfolio, Cultivar Diversification, Cultivation Efficiencies and Product Development
    TSX: ACB
    EDMONTON, June 12, 2018 /CNW/ - Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) and Anandia Laboratories Inc. ("Anandia") announced today that they have signed a binding term sheet whereby Aurora intends to acquire all of the issued and outstanding common shares of privately-held Anandia in an all share transaction valued at approximately $115 million on a fully diluted basis (the "Transaction").
    Led by CEO and co-founder Jonathan Page, PhD, one of the industry's most widely recognized cannabis experts, Anandia is considered the industry leader in science, genetics, and independent cannabis product testing. Dr. Page was the first scientist to sequence the cannabis genome and provide deep insights into the biosynthesis of cannabinoids and the interplay between cannabinoids and terpenes.
    Anandia's COO and co-founder, John Coleman, PhD, brings over 20 years of experience in drug research and commercialization as a natural product chemist. He previously worked in the biotech industry, most recently leading the team identifying new drug targets for the federally funded Centre for Drug Research and Development.
    Anandia's intellectual property ("IP") includes the exclusive rights to a number of key genes in the cannabinoid pathway, as well as patents pending for genetic markers. The strength of Anandia's expert staff, proprietary assets and know-how will provide Aurora with a very significant advantage in developing new cannabis cultivars. For instance, genome-based variety development and technological fortification can tailor metabolite (cannabinoid and terpene) profiles, improve disease resistance, enhance crop yield and optimize flowering time, and can be employed to develop specialized cultivars for oil production.
    In advance of the forthcoming legalization of the adult use market and the significant associated growth, Anandia intends to expand its R&D, product testing, and product development facilities to meet both domestic and international demand, including the development of:
    A 12,700 sq. ft. corporate head office, testing lab, R&D and tissue culture facility in Vancouver, British Columbia. This existing laboratory is undergoing security upgrades, with operations planned to coincide with legalization.
    A unique, 22,500 sq. ft., Aurora Larssen Projects Inc. ("ALP's") designed and constructed, Cannabis Innovation Centre, focused on cannabis breeding and genetics. This purpose-built greenhouse with an associated 10,000 sq. ft. laboratory building in Comox, BC is currently under construction and is located five minutes from a major airport, and has the option to expand to 100,000+ sq. ft. The project is on track with development permitting in-place, and construction planned for summer/fall 2018.
    Anandia follows a three-pronged approach to creating value for its clients licensed under Canada's Access to Cannabis for Medical Purposes Regulations ("ACMPR") and intends to continue to do so following completion of the Transaction:
    Independent Third-Party Analytical Testing: which includes cannabinoids, terpenes and contaminants (microorganisms, pesticides, heavy metals and others).
    Genetics: plant breeding, tissue culture and strain archiving, as well as genomics-based technologies.
    Product Development: development of cannabinoid preparations and formulations.
    Combining with Aurora gives Anandia access to significant new market opportunities in Canada and internationally through Aurora's global footprint. Furthermore, leveraging Aurora's capabilities and capacity in facility development, the combination will accelerate the construction of Anandia's testing and product development laboratory in Vancouver, and a unique, purpose-built cannabis breeding facility ahead of Canadian adult-use legalization,
    Anandia's Product Testing
    Anandia's cannabis testing services will remain operationally independent of Aurora. These services will remain intact and Anandia is committed to continuing to serve all clients, including Licensed Producers and patient-growers, and Anandia is committed to maintaining complete data confidentiality. Anandia will continue to build capacity to take on the increased sample volume arising from legalization, including expansion to its new testing facility in Vancouver.
    Management Commentary
    "This is a transformative acquisition that expands our science capabilities in the upstream segment of the seed-to-sale cannabis value chain, significantly boosting plant-based innovations in cultivation, enabling accelerated product development, and, ultimately, enhancing our margin profile going forward," said Terry Booth, CEO of Aurora. "Anandia has a fantastic, complementary corporate culture and some of the best and brightest minds in the cannabis industry, including Dr. Jonathan Page, the first scientist to sequence the cannabis genome. By adding Dr. Page and the Anandia team to the existing Aurora and CanniMed research infrastructure, we are assembling a unique, world-class research group to capitalize on the many exciting opportunities the cannabis plant offers society."
    Dr. Jonathan Page, Anandia's co-founder and CEO, added, "Anandia is already on its way to developing a world-leading library of cannabis genetics coupled with in-depth genomic analysis. We expect our breeding efforts to be accelerated through access to Aurora's financial resources and scientific expertise, as well as through the addition of Aurora's multiple cultivation sites. Anandia and Aurora are strong believers in research and science-based solutions. Joining forces with Aurora allows us to continue to provide best-in-class testing services to our customers, while rapidly advancing cannabis science for the benefit of patients, consumers and growers."
    Neil Belot, Chief Global Business Development Officer for Aurora, added, "The expansion of Anandia's physical infrastructure combined with Aurora's rapidly growing global footprint, creates a unique platform to pursue a wide variety of market opportunities. The Transaction will greatly boost our competitive advantage in developing marketable intellectual property and high-margin products, and help address diversified needs on a global basis."
    Terms of the Transaction
    Aurora will purchase 100% of the issued and outstanding shares from Anandia's shareholders in exchange for common shares of Aurora, based on the 20-day VWAP (to the Effective Date) equivalent to $115 million. In addition, each ACB share will be accompanied with a warrant exercisable for 1/2 of an ACB share at an exercise price equal to the issue price plus 10% with a term of 5 years.
    The parties intend to complete the Transaction by way of a plan of arrangement under the Business Corporations Act (British Columbia) subject to finalization of an Arrangement Agreement on acceptable terms to both parties. The closing of the Transaction is subject to customary closing conditions, including execution of definitive documentation, completion of satisfactory due diligence, receipt of approval of the shareholders of Anandia, and receipt of applicable third party and regulatory approvals, including that of the Supreme Court of British Columbia and the satisfaction of other conditions customary in transactions of this nature. The parties anticipate closing the Transaction in the coming weeks.

    Bron: investor.auroramj.com/#
  18. [verwijderd] 12 juni 2018 14:39
    man o man wat is acb bezig met kopen kopen hoop dat de koers niet weer down gaat door deze mededeling want er moet toch weer 115ml betaald worden. ze geven nu alleen maar uit om groter en groter te worden ben benieuwd wanneer dit terug komt in de koers en dus zorg voor een enorme koersstijging.
  19. [verwijderd] 12 juni 2018 14:43
    quote:

    eri09 schreef op 12 juni 2018 14:39:

    man o man wat is acb bezig met kopen kopen hoop dat de koers niet weer down gaat door deze mededeling want er moet toch weer 115ml betaald worden. ze geven nu alleen maar uit om groter en groter te worden ben benieuwd wanneer dit terug komt in de koers en dus zorg voor een enorme koersstijging.
    Hopelijk wordt het niet al te gek, ze mogen onderhand wel eens iets met de koers gaan doen.
8.267 Posts
Pagina: «« 1 ... 128 129 130 131 132 ... 414 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
THEON INTERNAT 11,020 +0,52 +4,95%
JUST EAT TAKEAWAY 15,720 +0,61 +4,04%
Akzo Nobel 57,520 +2,22 +4,01%
SIGNIFY NV 21,800 +0,62 +2,93%
EBUSCO HOLDING 1,072 +0,03 +2,60%
ADYEN NV 1.413,400 +35,00 +2,54%
HEIJMANS KON 29,650 +0,65 +2,24%
PROSUS 39,320 +0,77 +2,00%
Wolters Kluwer 160,300 +2,35 +1,49%
UMG 23,130 +0,32 +1,40%
ArcelorMittal 24,170 +0,33 +1,38%
CM.COM 5,960 +0,08 +1,36%
RELX 45,160 +0,58 +1,30%
ALLFUNDS GROUP 5,650 +0,07 +1,16%
Nedap N.V. 53,600 +0,60 +1,13%
UNILEVER PLC 57,160 +0,58 +1,03%
RANDSTAD NV 42,020 +0,41 +0,99%
AMG Critical Materials N.V. 14,430 +0,14 +0,98%
BESI 114,000 +1,00 +0,88%
ASML 664,100 +5,70 +0,87%
Wereldhave 14,020 +0,12 +0,86%
Accsys 0,585 +0,01 +0,86%
Heineken 70,640 +0,58 +0,83%
DSM FIRMENICH AG 104,800 +0,85 +0,82%
NX FILTRATION 4,030 +0,03 +0,75%
AEX 887,65 +5,92 +0,67%
Vastned 24,750 +0,15 +0,61%
Van Lanschot Kempen NV 42,700 +0,25 +0,59%
Brunel 8,850 +0,05 +0,57%
Galapagos 26,380 +0,12 +0,46%
Sligro 10,740 +0,04 +0,37%
Arcadis 62,650 +0,20 +0,32%
Corbion 22,040 +0,06 +0,27%
INPOST 16,610 +0,03 +0,18%
KPN 3,677 +0,01 +0,16%
Aperam 27,200 +0,04 +0,15%
AALBERTS NV 36,420 +0,04 +0,11%
AMX 871,13 +0,85 +0,10%
Ahold Delhaize 32,680 +0,03 +0,09%
OCI 11,080 +0,01 +0,09%
ASMI 511,800 +0,40 +0,08%
ASCX 1.227,42 +0,64 +0,05%
ABN AMRO BANK N.V. 14,720 +0,01 +0,03%
ACOMO 17,500 0,00 0,00%
CTP 15,200 0,00 0,00%
RENEWI 9,670 0,00 0,00%
TKH 30,780 0,00 0,00%
WDP 20,920 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
Kendrion 10,420 -0,42 -3,87%
B&S Group SA 4,425 -0,15 -3,17%
Vopak 43,140 -1,16 -2,62%
Eurocommercial Properties 23,150 -0,50 -2,11%
Avantium 2,060 -0,04 -1,90%
SBM Offshore 16,800 -0,32 -1,87%
Fagron 18,360 -0,32 -1,71%
Air France-KLM 7,288 -0,11 -1,43%
Alfen N.V. 11,250 -0,15 -1,27%
Fugro 17,000 -0,20 -1,16%
Basic-Fit 21,040 -0,22 -1,03%
Pharming 0,724 -0,01 -0,96%
Aegon 6,044 -0,06 -0,95%
Flow Traders 20,900 -0,20 -0,95%
EXOR NV 92,850 -0,80 -0,85%
BAM 4,032 -0,03 -0,79%
ForFarmers 3,205 -0,02 -0,77%
NN Group 43,640 -0,33 -0,75%
Philips Koninklijke 25,600 -0,19 -0,74%
NSI 19,600 -0,14 -0,71%
FASTNED 21,200 -0,15 -0,70%
ING 14,564 -0,09 -0,64%
SHELL PLC 30,535 -0,18 -0,60%
ASR Nederland 45,060 -0,24 -0,53%
AZERION 1,220 -0,01 -0,49%
PostNL 1,030 0,00 -0,48%
Sif Holding 12,380 -0,06 -0,48%
TomTom 5,250 -0,03 -0,47%
IMCD 141,800 -0,30 -0,21%
JDE PEET'S 18,860 -0,01 -0,05%
vlag naam koers verschil relatief verschil
AEX 887,65 +5,92 +0,67%
AEX GR 3.481,67 +23,25 +0,67%
Germany40^ 19.923,00 +296,55 +1,51%
FTSE 100 8.312,89 +25,59 +0,31%
EURO50 4.852,81 +56,61 +1,18%
US30^ 44.797,40 -116,30 -0,26%
Nasd100^ 21.165,20 +259,40 +1,24%
US500^ 6.047,76 +16,71 +0,28%
Japan225^ 38.619,60 +360,30 +0,94%
VD-NEW 14,86 +0,23 +1,59%
#/^ Index indications calculated real time, zie disclaimer